Identification of Serum Metabolites Associating with Chronic Kidney Disease Progression and Anti-Fibrotic Effect of 5-Methoxytryptophan
Dan-Qian Chen,Gang Cao,Hua Chen,Christos P. Argyopoulos,Hui Yu,Wei Su,Lin Chen,David C. Samuels,Shougang Zhuang,George P. Bayliss,Shilin Zhao,Xiao-Yong Yu,Nosratola D. Vaziri,Ming Wang,Dan Liu,Jia-Rong Mao,Shi-Xing Ma,Jin Zhao,Yuan Zhang,You-Quan Shang,Huining Kang,Fei Ye,Xiao-Hong Cheng,Xiang-Ri Li,Li Zhang,Mei-Xia Meng,Yan Guo,Ying-Yong Zhao
DOI: https://doi.org/10.1038/s41467-019-09329-0
IF: 16.6
2019-01-01
Nature Communications
Abstract:Early detection and accurate monitoring of chronic kidney disease (CKD) could improve care and retard progression to end-stage renal disease. Here, using untargeted metabolomics in 2155 participants including patients with stage 1–5 CKD and healthy controls, we identify five metabolites, including 5-methoxytryptophan (5-MTP), whose levels strongly correlate with clinical markers of kidney disease. 5-MTP levels decrease with progression of CKD, and in mouse kidneys after unilateral ureteral obstruction (UUO). Treatment with 5-MTP ameliorates renal interstitial fibrosis, inhibits IκB/NF-κB signaling, and enhances Keap1/Nrf2 signaling in mice with UUO or ischemia/reperfusion injury, as well as in cultured human kidney cells. Overexpression of tryptophan hydroxylase-1 (TPH-1), an enzyme involved in 5-MTP synthesis, reduces renal injury by attenuating renal inflammation and fibrosis, whereas TPH-1 deficiency exacerbates renal injury and fibrosis by activating NF-κB and inhibiting Nrf2 pathways. Together, our results suggest that TPH-1 may serve as a target in the treatment of CKD.